TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

85 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2023-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC

NCT02353741

Non Small Cell Lung Cancer

TERMINATED PHASE2

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

NCT02788058

Lung Adenocarcinoma EGFR Positive Non-small Cell Lung Cancer

UNKNOWN PHASE2

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

NCT06613633

Third-generation TKI NSCLC (Advanced Non-small Cell Lung Cancer)

COMPLETED

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

NCT03544814

Lung Adenocarcinoma EGFR Activating Mutation

COMPLETED PHASE2

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

NCT04304638

Non Small Cell Lung Cancer Stage III Non-small-cell Lung Cancer EGFR Mutation-Related Tumors

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tyrosine kinase inhibitor (TKI) has been widely accepted as the first-line therapy for stage IV NSCLC with active mutation of EGFR. Olio-metastasis is a disease status between localized and extended status of disease, namely with the limited number of lesions, which is generally defined as ≤ 5. A couple of phase II studies have shown that consolidation local management was able to prolong the local-regional tumor control and might further improve overall survival (OS) for oligo-metastatic NSCLC who have gained disease control from systemic therapy. However, there is lack of data regarding whether local radiotherapy (RT) could improve progression free survival (PFS) and OS for NSCLC with active EGFR mutation who have benefited from TKI. In this phase II trial with single arm, we aim to investigate the clinical efficacy and toxicity profile of local radiotherapy on all disease sites for EGFR-mutant oligo-metastatic NSCLC (no more than 3 metastatic lesions) who did not experience disease progression after at least 3 months of TKI therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Cancer Metastatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Local therapy

Consolidation local radiotherapy

Group Type EXPERIMENTAL

Local radiation therapy

Intervention Type RADIATION

Local radiotherapy on all sites of disease including primary and metastatic lesions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Local radiation therapy

Local radiotherapy on all sites of disease including primary and metastatic lesions

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 and ≤75;
* ECOG performance status 0-1;
* Patients must provide study specific informed consent prior to study entry;
* Pathologically or cytologically diagnosed as NSCLC;
* EGFR activating mutation to TKI approved by histology, cytology or circulation tumor DNA;
* Stage IV NSCLC with ≤ 3 metastatic lesions (AJCC, 8th ed.) confirmed by meticulous radiographic examination. Brain MRI and 18F PET/CT is strongly recommended unless there is a contraindication;
* Patients have received≥3 months of TKI therapy and do not received disease progression;
* HB ≥ 10.0 g/dL;
* Absolute number of neutrophil granulocyte ≥ 1.5 × 109/L;
* Absolute number of PLT ≥ 100 × 109/L;
* Total bilirubin ≤ 1.5 folds of the maximum extent;
* ALT and AST ≤ 2.0 folds of the maximum extent;
* Cr ≤ 1.25 folds of the maximum extent and Ccr ≥ 60mLl/min.

Exclusion Criteria

* Patients have received thoracic radiotherapy before;
* Malignant pleural effusion, pericardial effusion or peritoneal effusion;
* Patients have severe pulmonary comorbidity, such as ILD, COPD or other active pulmonary disease;
* Any unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, CHF (NYHA ≥ II), MI within 6 months of enrollment, severe arrhythmia requiring medication，hepatic, nephric or metabolic disease;
* HIV infection；
* Pregnancy or lactation women;
* ECOG status ≥2；
* Mixed SCLC component;
* Other factors that is considered ineligible.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No